Chronic Atrophic Gastritis
Conditions
Interventions
Experimental group,:Shenye Xiaozheng Formula Granules, one packet per dose, dissolved in warm water, to be taken before meals, twice daily (morning and evening).
Control group:Traditional Chinese medicine granule simulator, one packet per dose, dissolved in warm water, to be taken before meals, twice daily (morning and evening).
Sponsors
Wangjing Hospital China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1)Meeting the diagnostic criteria for chronic atrophic gastritis confirmed by electronic gastroscopy and gastric mucosal histopathological examination before enrollment with clear evidence of mild to moderate gastric dysplasia; 2)Meeting the diagnostic criteria for the syndrome of liver qi stagnation and blood stasis; 3)Have not taken Chinese medicine/herbal medicine within one week prior to enrollment; 4)Aged =18 years and =75 years with no gender restrictions; 5)Voluntarily participate in the trial have a certain level of literacy and be able to sign the informed consent form; 6)Only patients who are permanent residents of Beijing and can ensure follow-up during the treatment period are included; 7)No use of anticoagulants such as aspirin or warfarin and no coagulation disorders.
Exclusion criteria
Exclusion criteria: Patients who meet one or more of the following criteria should be excluded: 1)Suspected high-grade intraepithelial neoplasia or esophagogastric tumors; 2)History of endoscopic or surgical treatment for high-grade intraepithelial neoplasia or tumors in the esophagogastric region; 3)Patients with malignant tumors in other parts of the body; 4)Patients with severe diseases of organs such as the heart brain liver or kidneys; 5)Patients with an allergic constitution or a history of allergies to multiple drugs (two or more) or known drugs or components used in this study; 6)Women who are breastfeeding or pregnant; female participants must take contraceptive measures; 7)Patients with abnormal mental status who are unable to complete the trial; 8)Patients who are currently participating in other drug clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Observe changes in gastric mucosal color, fold morphology, and vascular transparency;Efficacy rate based on histopathological changes or symptom scores at week 24;TCM Syndrome Score;TCM Symptom Score; | — |
Countries
China
Contacts
Public ContactWei wei
Wangjing Hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed